Pharmaceutical company enters consent agreement to address abuse of dominance concerns
The Competition Bureau announced on March 24 that it entered into a consent agreement with Isologic Innovative Radiopharmaceuticals Inc. in order to “address competition concerns with its contracting practices in the...To view the full article, register now.
Already a subscriber? Click here to view full article